News

benzinga_article
2025.11.18 21:19
Kazia Therapeutics shares are trading higher after the company reported an initial immune-complete response in a stage IV triple-negative breast cancer patient treated under an FDA-authorized expanded access protocol combining paxalisib with pembrolizumab and chemotherapy.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer